Evoke Pharma Stock (NASDAQ:EVOK)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$4.89

52W Range

$3.54 - $13.80

50D Avg

$4.95

200D Avg

$5.55

Market Cap

$7.22M

Avg Vol (3M)

$399.61K

Beta

0.35

Div Yield

EVOK Company Profile

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Sep 25, 2013

Website

EVOK Performance

EVOK Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$5.18M	$2.51M	$1.62M
Operating Income	$-7.43M	$-7.79M	$-8.15M
Net Income	$-7.79M	$-8.16M	$-9.03M
EBITDA	$-7.43M	$-7.72M	$-8.14M
Basic EPS	$-2.33	$-2.60	$-3.37
Diluted EPS	$-2.33	$-2.60	$-3.37

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q4 23Mar 14, 24 | 9:33 PM

Q4 22Mar 21, 23 | 6:39 PM

Q3 22Nov 09, 22 | 8:46 PM

Peer Comparison

Ticker	Company
DERM	Journey Medical Corporation
IXHL	Incannex Healthcare Limited
BFRI	Biofrontera Inc.
CPIX	Cumberland Pharmaceuticals Inc.
PROC	Procaps Group S.A.
AQST	Aquestive Therapeutics, Inc.
SHPH	Shuttle Pharmaceuticals Holdings, Inc.
RGC	Regencell Bioscience Holdings Limited
PTPI	Petros Pharmaceuticals, Inc.
AKAN	Akanda Corp.
PRFX	PainReform Ltd.
AVDL	Avadel Pharmaceuticals plc